Prostate cancer (PCa) is the most common malignant tumour affecting the urinary system. In 2020, it ranked fourth in incidence among all cancers, comprising 7.3% of all new cancer cases. Notably, PCa was the second most frequently diagnosed cancer in men globally, accounting for 14.1% of new cancer cases in males1.
Castration-Resistant Prostate Cancer (CRPC) is characterised by disease progression despite androgen deprivation therapy, with serum testosterone maintained at castration levels. Disease progression can be monitored through prostate-specific antigen (PSA) testing or imaging evidence2.
Metastasis occurs when cancer spreads from its original site to distant parts of the body. Metastatic PCa includes metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). These subtypes of metastatic PCa exhibit the characteristics of hormone sensitivity2.
Generally, CRPC is relatively late-stage of the disease.
In 2020, there were over 1,414,259 estimated new cases of PCa worldwide, with an age-standardised incidence of 37.5 per 100,000 males in higher human development index countries1.
5% (3-8%) prevalence at age <30 years to a prevalence of 59% (48-71%) by age >79 years3.
PCa also significantly contributes to cancer-related deaths, with 375,304 deaths in 2020 worldwide, positioning as the fifth most common cause of cancer-related mortality in men1.
